Acamprosate
آکامپروسات
🧠 Nervous SystemAlcohol abstinence maintenance
Market / country: 🇺🇸 USA
Campral (US)
🧮 Dose calculator
Alcohol dependence · Regimen source: FDA Acamprosate DR · 2
- • Start as soon as possible after withdrawal once abstinent; continue through relapse. Preferably with meals. FDA Acamprosate DR · 2
Enter age (weight is optional for this regimen).
🛡️ Safety & information
Contraindications
- ⛔ Hypersensitivity; severe renal impairment. FDA Acamprosate DR · 4
Formulations
- 333 mg delayed-release tablet — tablet 🇺🇸 USA FDA Acamprosate DR · 3
👥 Special populations
- 🤰 PregnancyUse with caution
Label states no clear risk or has limited data; use only if needed, under medical advice. FDA Acamprosate DR · 8.1
“Acamprosate calcium should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.”
- 🤱 BreastfeedingUse with caution
Label: use with caution while breastfeeding; see the label text. FDA Acamprosate DR · 8.3
“Because many drugs are excreted in human milk, caution should be exercised when acamprosate calcium is administered to a nursing woman.”
- 👶 ChildrenUse with caution
The label has conditions, age limits or notes for children; the label sentence is quoted below. FDA Acamprosate DR · 8.4
“The safety and efficacy of acamprosate calcium have not been established in the pediatric population.”
- 👴 Older adultsUse with caution
Label: use with caution in older adults, usually starting at the low end of the dose range. FDA Acamprosate DR · 8.5
“Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function [ see Clinical Pharmacology ( 12.3 ), Adverse Reactions ( 6.1 ), and Dosage and Administration ( 2.1 ) ].”
- ⚥ Females & males of reproductive potentialNo data
The source for this drug has no section for this group.
🔗 Reference links
- FDA (approval record)ANDA218984
- DailyMed (FDA label)FDA Acamprosate DR
- MedlinePlus (NIH)Acamprosate
- WHO ATC/DDDN07BB03
- Darooyab (Iran)Acamprosate
🇮🇷 Registered in Iran Darooyab · G-1218/Acamprosate
Dosage forms with Iranian generic codes, per Darooyab.
- 09245 · ACAMPROSATE CALCIUM 333MG TAB · قرص آکامپروسات کلسیم ۳۳۳ میلیگرم
📚 Reference status for this drug
Shows which sources have references recorded for this drug and which do not.
- FDA label (DailyMed)✅ PresentFDA Acamprosate DR · 3FDA Acamprosate DR · 2FDA Acamprosate DR · 4FDA Acamprosate DR · SPL approval / marketing categoryFDA Acamprosate DR · 8.1FDA Acamprosate DR · 8.3FDA Acamprosate DR · 8.4FDA Acamprosate DR · 8.5
- UK SmPC (eMC / MHRA)❌ Not present
- Published guideline❌ Not present
- Licensed reference (medical school)❌ Not present
- Iranian leaflet (IFDA)❌ Not present
- Pharmacy website (secondary, unreliable)✅ PresentDarooyab · G-1218/Acamprosate
- Clinical review⚠ Unverified